CD274 and neoplasm: Besides monitoring CAR‐T cell therapy, the group of Sengupta was able to monitor the efficacy of immunotherapy in vivo by designing 2‐in‐1 reporter NPs.[38] The PD‐L1 reporter NPs produced were found to stimulate the level of activated‐caspase‐3 in the B16‐F10 melanoma tumor model, leading to promoted T cell trafficking activity at tumor sites, in addition to the production of a strong fluorescence signal.[38] Accordingly, these types of reporter NPs have the capacity to both deliver and report on therapeutic efficiency in real time.